Kim Henriksen is Director of Endocrinology and Neuroscience at Nordic Bioscience. He joined Nordic Bioscience in 2002 and was appointed to his current role in 2018.

His research focuses on the identification and development of novel peptide-based therapies for metabolic diseases, including obesity, non-alcoholic steatohepatitis (NASH), and type 2 diabetes. This work has led to the patenting and development of two peptide families, KBPs and OXMs, both of which are rapidly advancing toward clinical development.